1. Market Research
  2. > BrainCells Inc. – Product Pipeline Review – 2013

BrainCells Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 31 pages

BrainCells Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “BrainCells Inc. - Product Pipeline Review - 2013” provides data on the BrainCells Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BrainCells Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from BrainCells Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- BrainCells Inc. - Brief BrainCells Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BrainCells Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of BrainCells Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the BrainCells Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate BrainCells Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of BrainCells Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the BrainCells Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with BrainCells Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of BrainCells Inc. and identify potential opportunities in those areas.

Table Of Contents

BrainCells Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
BrainCells Inc. Snapshot 4
BrainCells Inc. Overview 4
Key Information 4
Key Facts 4
BrainCells Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
BrainCells Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
BrainCells Inc. - Pipeline Products Glance 10
BrainCells Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
BrainCells Inc. - Drug Profiles 12
BCI-1038 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
BCI-1206 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
BCI-1283 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
BrainCells Inc. - Pipeline Products by Route of Administration 15
BrainCells Inc. - Pipeline Products By Mechanism of Action 16
BrainCells Inc. - Recent Pipeline Updates 17
BrainCells Inc. - Dormant Projects 18
BrainCells Inc. - Discontinued Pipeline Products 19
Discontinued Pipeline Product Profiles 19
sabcomeline hydrochloride 19
BrainCells Inc. - Locations And Subsidiaries 20
Head Office 20
Financial Deals Landscape 21
BrainCells Inc., Deals Summary 21
BrainCells Inc., Pharmaceuticals and Healthcare, Deal Details 22
Venture Financing 22
BrainCells Raises Additional US$2 Million In Venture Financing 22
BrainCells Secures US$0.99 Million In Venture Financing 23
BrainCells Secures US$50 Million In Series B Financing 24
Licensing Agreements 27
Proximagen Group Enters Into Licensing Agreement With BrainCells 27
Taisho Pharma Enters Into Licensing Agreement with BrainCells 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31



List of Tables

BrainCells Inc., Key Information 4
BrainCells Inc., Key Facts 4
BrainCells Inc. - Pipeline by Indication, 2013 7
BrainCells Inc. - Pipeline by Stage of Development, 2013 8
BrainCells Inc. - Monotherapy Products in Pipeline, 2013 9
BrainCells Inc. - Phase II, 2013 10
BrainCells Inc. - Phase I, 2013 11
BrainCells Inc. - Pipeline By Route of Administration, 2013 15
BrainCells Inc. - Pipeline Products By Mechanism of Action, 2013 16
BrainCells Inc. - Recent Pipeline Updates, 2013 17
BrainCells Inc. - Dormant Developmental Projects,2013 18
BrainCells Inc. - Discontinued Pipeline Products, 2013 19
BrainCells Inc., Deals Summary 21
BrainCells Raises Additional US$2 Million In Venture Financing 22
BrainCells Secures US$0.99 Million In Venture Financing 23
BrainCells Secures US$50 Million In Series B Financing 24
Proximagen Group Enters Into Licensing Agreement With BrainCells 27
Taisho Pharma Enters Into Licensing Agreement with BrainCells 29



List of Figures

BrainCells Inc. - Pipeline by Indication, 2013 6
BrainCells Inc. - Pipeline by Stage of Development, 2013 8
BrainCells Inc. - Monotherapy Products in Pipeline, 2013 9
BrainCells Inc. - Pipeline Products By Mechanism of Action, 2013 16

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.